A Study of HLD-0117 in Patients With Metastatic Breast Cancer
Recruiting
Phase 1
Interventional Study
Metastatic Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 33 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female (assigned at birth), ≥18 years old, and able to provide informed consent
* Histologically confirmed metastatic or locally advanced breast cancer
* Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist
* Prior treatmen…
Contacts